FI70573C - Analogifoerfarande foer framstaellning av terapeutiskt aktiv 2,6-dimetyl-4-(2,3-diklorfenyl)-1,4-dihydro- pyridin-3,5-dikarboxylsyra-3-metylester-5-etylester - Google Patents

Analogifoerfarande foer framstaellning av terapeutiskt aktiv 2,6-dimetyl-4-(2,3-diklorfenyl)-1,4-dihydro- pyridin-3,5-dikarboxylsyra-3-metylester-5-etylester Download PDF

Info

Publication number
FI70573C
FI70573C FI792058A FI792058A FI70573C FI 70573 C FI70573 C FI 70573C FI 792058 A FI792058 A FI 792058A FI 792058 A FI792058 A FI 792058A FI 70573 C FI70573 C FI 70573C
Authority
FI
Finland
Prior art keywords
sub
formula
compound
formulation
dimethyl
Prior art date
Application number
FI792058A
Other languages
English (en)
Finnish (fi)
Other versions
FI792058A (fi
FI70573B (fi
Inventor
Peder Bernhard Berntsson
Stig Aoke Ingemar Carlsson
Jan Oernulf Gaarder
Bengt Richard Ljung
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20335348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI70573(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of FI792058A publication Critical patent/FI792058A/fi
Application granted granted Critical
Publication of FI70573B publication Critical patent/FI70573B/fi
Publication of FI70573C publication Critical patent/FI70573C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI792058A 1978-06-30 1979-06-29 Analogifoerfarande foer framstaellning av terapeutiskt aktiv 2,6-dimetyl-4-(2,3-diklorfenyl)-1,4-dihydro- pyridin-3,5-dikarboxylsyra-3-metylester-5-etylester FI70573C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE7807404 1978-06-30
SE7807404A SE429652B (sv) 1978-06-30 1978-06-30 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester

Publications (3)

Publication Number Publication Date
FI792058A FI792058A (fi) 1979-12-31
FI70573B FI70573B (fi) 1986-06-06
FI70573C true FI70573C (fi) 1986-09-24

Family

ID=20335348

Family Applications (1)

Application Number Title Priority Date Filing Date
FI792058A FI70573C (fi) 1978-06-30 1979-06-29 Analogifoerfarande foer framstaellning av terapeutiskt aktiv 2,6-dimetyl-4-(2,3-diklorfenyl)-1,4-dihydro- pyridin-3,5-dikarboxylsyra-3-metylester-5-etylester

Country Status (24)

Country Link
US (1) US4264611A (da)
EP (1) EP0007293B1 (da)
JP (1) JPS559083A (da)
AT (1) ATE1237T1 (da)
AU (1) AU529116B2 (da)
BG (1) BG61420B2 (da)
CA (1) CA1117530A (da)
CS (1) CS241021B2 (da)
CY (1) CY1299A (da)
DD (1) DD144667A5 (da)
DE (1) DE2963150D1 (da)
DK (1) DK148978C (da)
FI (1) FI70573C (da)
HK (1) HK60585A (da)
HU (1) HU178568B (da)
IE (1) IE48650B1 (da)
LU (2) LU88666I2 (da)
NL (2) NL930054I2 (da)
NO (3) NO151965C (da)
NZ (1) NZ190809A (da)
SE (1) SE429652B (da)
SG (1) SG26085G (da)
SU (2) SU856380A3 (da)
ZA (1) ZA792804B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2935451A1 (de) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
SE7910521L (sv) * 1979-12-20 1981-06-21 Haessle Ab Nya 2-metyl-6-substituerade-4-(2,3-disubstituerad fenyl)-1,4-dihydropyridin-3,5-diestrar med hypotesiva egenskaper, samt forfarande for deras framstellning, och farmaceutiska beredningar innehallande desamma
IL68604A0 (en) * 1982-05-21 1983-09-30 Haessle Ab Processes for preparing therapeutically active dihydropyridines and intermediates for the processes
US4656181A (en) * 1982-11-24 1987-04-07 Cermol S.A. Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
FI852359L (fi) * 1984-06-27 1985-12-28 Hoffmann La Roche Dihydropyridinderivat.
US4757071A (en) * 1984-12-14 1988-07-12 Nisshin Flour Milling Co., Ltd. 1,4-dihydropyridine derivatives, and pharmaceutical compositions containing same, useful for treating cardiovascular diseases
DE3447169A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Optisch aktive nitrodihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
DE3447170A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Mischung unterschiedlicher dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
NZ220022A (en) * 1986-04-22 1990-04-26 Byk Gulden Lomberg Chem Fab 1,4-dihydropyridine derivatives and pharmaceutical compositions
US4920225A (en) * 1986-12-22 1990-04-24 Laboratoires Syntex S.A. Resolution of 1,4-dihydropyridine derivatives
JPS63255071A (ja) * 1987-04-14 1988-10-21 株式会社　岡田吾作郎商店 磁石内蔵健康棒
AT391269B (de) * 1988-12-30 1990-09-10 Burghart Kurt Pharmazeutische zubereitung
US5310917A (en) * 1991-09-13 1994-05-10 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropydrines
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
JPH07501551A (ja) * 1991-12-02 1995-02-16 セプラコア，インコーポレーテッド 光学的に純粋なｓ（−）フェロジピンを用いる，高血圧，狭心症および他の疾患を治療するための方法および組成物
EP0657432B1 (de) 1993-12-10 2003-03-12 Bayer Ag Phenyl-substituierte 1,4-Dihydropyridine mit cerebraler Aktivität
DE4430639A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5977369A (en) * 1995-12-28 1999-11-02 Napp Technologies, Inc. Process to prepare dihydropyridine and derivatives thereof
SE9600086D0 (sv) * 1996-01-10 1996-01-10 Astra Ab New manufacturing process
IT1283793B1 (it) * 1996-08-23 1998-04-30 Lusochimica Spa Processo per la preparazione di diidropiridine
WO2000005209A1 (en) * 1998-07-23 2000-02-03 Lin, Tong-Ho GUAIACOXYPROPANOLAMINES WITH α/β-ADRENERGIC BLOCKING ACTIVITY
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
EP1285655B1 (en) * 2000-04-11 2007-05-30 Sankyo Company, Limited Stabilized pharmaceutical compositions containing the calcium channel blocker azelnidipine
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
ES2362998T3 (es) 2002-08-19 2011-07-18 Pfizer Inc. Terapia de combinación para enfermedades hiperproliferativas.
GEP20084406B (en) * 2003-05-30 2008-06-25 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20060147520A1 (en) * 2004-07-26 2006-07-06 Curtis Ruegg Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2111863B1 (en) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
CN101494980A (zh) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 HMG-CoA还原酶抑制剂的多晶型形式及其应用
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2009032286A2 (en) 2007-09-06 2009-03-12 Nektar Therapeutics Al, Corporation Oligomer-calcium channel blocker conjugates
JP2011503085A (ja) * 2007-11-07 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アンギオテンシン変換酵素阻害剤及びバソプレッシン受容体拮抗薬を含む複合治療
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2012123966A1 (en) 2011-03-04 2012-09-20 Arch Pharmalabs Limited Process for the preparation of 4 -substituted -1, 4-dihydropyridines
CN102827068A (zh) * 2011-06-17 2012-12-19 张锐豪 一种4-(2, 3-二氯苯基)-2, 6-二甲基-1, 4-二氢-5-甲氧基羰基-3-吡啶羧酸的制备方法
MX2014002163A (es) 2011-08-26 2014-09-25 Wockhardt Ltd Métodos para el tratamiento de desórdenes cardiovasculares.
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN104177286A (zh) * 2014-08-11 2014-12-03 广东东阳光药业有限公司 一种地平类药物的制备方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
KR101824982B1 (ko) 2015-10-07 2018-02-02 엘지전자 주식회사 차량 및 그 제어방법
CN107952483B (zh) * 2017-12-18 2020-07-28 万华化学集团股份有限公司 一种催化剂，使用该催化剂的反应器，以及一种制备β-苯乙醇的方法
CN108840819B (zh) * 2018-04-02 2021-07-30 常州瑞明药业有限公司 一种非洛地平的制备方法
CA3103616A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441648A (en) * 1967-02-07 1969-04-29 Smithkline Corp Compositions and methods for lowering blood pressure with 1,4-dihydropyridines
DE1670824C3 (de) * 1967-03-20 1978-08-03 Bayer Ag, 5090 Leverkusen 1,4-Dihydropyridin-33-dicarbonsäurealkylester
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117573C3 (de) * 1971-04-10 1978-07-27 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von unsymmetrischen l,4-Dihydropyridin-3,5dicarbonsäureestern, sowie ihre Verwendung als Arzneimittel
DE2210672C3 (de) * 1972-03-06 1980-03-20 Bayer Ag, 5090 Leverkusen N-substituierte unsymmetrische 1 ^-Dihydropyridin-S^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof

Also Published As

Publication number Publication date
LU88306I2 (fr) 1994-05-04
NO151965B (no) 1985-04-01
NO792112L (no) 1980-01-03
US4264611B1 (da) 1984-07-17
DK148978C (da) 1986-08-18
EP0007293B1 (en) 1982-06-23
DE2963150D1 (en) 1982-08-12
US4264611A (en) 1981-04-28
NL940012I1 (nl) 1994-08-01
HK60585A (en) 1985-08-23
IE48650B1 (en) 1985-04-03
CS241021B2 (en) 1986-03-13
SE429652B (sv) 1983-09-19
CY1299A (en) 1985-10-18
SE7807404L (sv) 1979-12-31
HU178568B (en) 1982-05-28
NL930054I2 (nl) 1994-02-16
NO151965C (no) 1985-07-10
FI792058A (fi) 1979-12-31
CA1117530A (en) 1982-02-02
SG26085G (en) 1986-01-24
NL930054I1 (nl) 1993-09-01
EP0007293A1 (en) 1980-01-23
IE791217L (en) 1979-12-30
ZA792804B (en) 1980-06-25
LU88666I2 (fr) 1996-02-01
NZ190809A (en) 1982-03-09
JPS559083A (en) 1980-01-22
ATE1237T1 (de) 1982-07-15
NO1994026I1 (no) 1994-12-21
DD144667A5 (de) 1980-10-29
FI70573B (fi) 1986-06-06
AU529116B2 (en) 1983-05-26
DK275079A (da) 1979-12-31
JPS6121550B2 (da) 1986-05-27
SU856380A3 (ru) 1981-08-15
BG61420B2 (bg) 1997-07-31
DK148978B (da) 1985-12-09
NO1996006I1 (no) 1996-06-24
SU915799A3 (en) 1982-03-23
AU4831679A (en) 1980-02-07

Similar Documents

Publication Publication Date Title
FI70573C (fi) Analogifoerfarande foer framstaellning av terapeutiskt aktiv 2,6-dimetyl-4-(2,3-diklorfenyl)-1,4-dihydro- pyridin-3,5-dikarboxylsyra-3-metylester-5-etylester
FI90543B (fi) Menetelmä lääkeaineina käyttökelpoisten dihydropyridiinin johdannaisten valmistamiseksi
FR2615191A1 (fr) Nouveaux benzo(b)pyrannes et pyrannopyridines, leur preparation et leur utilisation comme medicaments
FI86425B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 6-benzoxazinyl- och 6-benzotiazinyl-2,3,4,5- tetrahydropyridazin-3-oner.
JPS63297365A (ja) ジヒドロピリジン類
FR2562892A1 (fr) Nouveaux dihydropyridinyldicarboxylates amides et esters, utilisation de ces composes comme medicament, compositions pharmaceutiques comprenant de tels composes et procede pour la preparation de tels composes
EP0446141A1 (fr) Nouveaux dérivés d'imidazo [1,2-C] quinazoline leur procédé de préparation et les compositions pharmaceutiques les renfermant
US4576934A (en) Antihypertensive dihydropyridine-5-phosphonic acid cyclic esters
US4782069A (en) 1,4-Dihydropiridines and their use as antithrombotic drugs
EP0562936A1 (fr) Imidazolines N-substituées par un groupement biphénylméthyle, leur préparation, les compositions pharmaceutiques en contenant
AU628995B2 (en) Novel thienopyran derivatives, a process for their preparation and their use
SK48094A3 (en) Condensated chinolyl-dihydropyridines, method of their production, treatments containing these matters, method of production and using of these compounds
SK158692A3 (en) 2-amino-5-cyano-1,4-dihydropyridines, method of their preparation and their use in medicines
FR2596051A1 (fr) Nouveaux derives de la purine, leur preparation et leur utilisation comme medicaments
KR900005956B1 (ko) 1,4-디하이드로피리딘-3,5-디카르복실산의 비대칭 에스테르 유도체의 제조방법
SU1731049A3 (ru) Способ получени симметричного эфира 4-замещенной 1,4-дигидропиридин-3,5-дикарбоновой кислоты или его физиологически приемлемых солей
Taylor et al. 2-(2-Aryl-2-oxoethylidene)-1, 2, 3, 4-tetrahydropyridines. Novel isomers of 1, 4-dihydropyridine calcium channel blockers
JPS62174050A (ja) ３−アミノカルボニル−１，４−ジヒドロピリジン−５−カルボン酸誘導体、その製法および医薬組成物
US4280998A (en) 1,4-Dihydropyridazine-3-carboxylic acid derivatives, a process for their preparation and their use as antihypertensives
CH679859A5 (da)
CA1205471A (en) Dihydropyridines
RU2155751C2 (ru) Производные 1,4-дигидропиридина, смесь их изомеров или отдельные изомеры, фармацевтическая композиция на их основе и 2-хлор-3-цианобензальдегид
FI85491B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fosfonsyraderivat.
SE442298B (sv) 2,6-dimetyl-4-(2,3-diklorfenyl)-1,4-dihydropyridin-3,5-dikarboxylsyra-3-metylester-5-etylester i optisk aktiv form
JPH0699458B2 (ja) ジヒドロピリジン−５−ホスホン酸環状エステル類

Legal Events

Date Code Title Description
MA Patent expired
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L82

Extension date: 20030121

ND Supplementary protection certificate (spc) granted
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L98

Extension date: 20040629

MA Patent expired

Owner name: AKTIEBOLAGET HAESSLE